Payden & Rygel Increases Holdings in Eli Lilly and Company (NYSE:LLY)

Payden & Rygel raised its stake in Eli Lilly and Company (NYSE:LLYGet Rating) by 3.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 153,025 shares of the company’s stock after buying an additional 5,100 shares during the period. Eli Lilly and accounts for 2.2% of Payden & Rygel’s holdings, making the stock its 8th largest holding. Payden & Rygel’s holdings in Eli Lilly and were worth $43,822,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Marietta Wealth Management LLC lifted its holdings in Eli Lilly and by 30.3% in the first quarter. Marietta Wealth Management LLC now owns 16,278 shares of the company’s stock valued at $4,662,000 after buying an additional 3,787 shares during the period. Integrated Wealth Concepts LLC increased its position in shares of Eli Lilly and by 10.3% during the fourth quarter. Integrated Wealth Concepts LLC now owns 17,255 shares of the company’s stock worth $4,766,000 after acquiring an additional 1,613 shares in the last quarter. Vestmark Advisory Solutions Inc. boosted its holdings in Eli Lilly and by 3.1% during the fourth quarter. Vestmark Advisory Solutions Inc. now owns 12,157 shares of the company’s stock worth $3,358,000 after purchasing an additional 364 shares during the last quarter. Wedbush Securities Inc. boosted its holdings in Eli Lilly and by 110.1% during the fourth quarter. Wedbush Securities Inc. now owns 11,235 shares of the company’s stock worth $3,103,000 after purchasing an additional 5,887 shares during the last quarter. Finally, Lincoln National Corp boosted its holdings in Eli Lilly and by 4.9% during the fourth quarter. Lincoln National Corp now owns 9,656 shares of the company’s stock worth $2,667,000 after purchasing an additional 455 shares during the last quarter. Hedge funds and other institutional investors own 82.75% of the company’s stock.

In other news, major shareholder Lilly Endowment Inc sold 200,000 shares of the business’s stock in a transaction on Friday, May 27th. The stock was sold at an average price of $318.98, for a total value of $63,796,000.00. Following the sale, the insider now owns 104,833,810 shares of the company’s stock, valued at approximately $33,439,888,713.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction dated Wednesday, June 1st. The stock was sold at an average price of $313.44, for a total value of $313,440.00. Following the sale, the chief accounting officer now owns 6,274 shares of the company’s stock, valued at approximately $1,966,522.56. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 848,630 shares of company stock worth $259,239,945. Corporate insiders own 0.12% of the company’s stock.

Shares of Eli Lilly and stock traded up $2.64 on Thursday, reaching $309.33. 8,220 shares of the company were exchanged, compared to its average volume of 2,977,431. The stock’s 50 day moving average price is $297.48 and its 200-day moving average price is $274.96. The company has a debt-to-equity ratio of 1.60, a current ratio of 1.27 and a quick ratio of 0.98. The company has a market cap of $293.91 billion, a P/E ratio of 45.44, a price-to-earnings-growth ratio of 2.06 and a beta of 0.40. Eli Lilly and Company has a 1-year low of $217.00 and a 1-year high of $324.08.

Eli Lilly and (NYSE:LLYGet Rating) last posted its quarterly earnings data on Thursday, April 28th. The company reported $2.62 earnings per share for the quarter, beating the consensus estimate of $2.32 by $0.30. Eli Lilly and had a return on equity of 97.58% and a net margin of 20.90%. The business had revenue of $7.81 billion during the quarter, compared to the consensus estimate of $7.29 billion. During the same period in the prior year, the company earned $1.87 earnings per share. The company’s revenue was up 14.8% compared to the same quarter last year. On average, research analysts predict that Eli Lilly and Company will post 8.27 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, June 10th. Stockholders of record on Monday, May 16th were given a $0.98 dividend. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.27%. The ex-dividend date was Friday, May 13th. Eli Lilly and’s dividend payout ratio is currently 58.07%.

LLY has been the topic of a number of recent research reports. Morgan Stanley upped their price target on shares of Eli Lilly and from $364.00 to $369.00 in a research note on Friday, April 29th. Daiwa Capital Markets assumed coverage on shares of Eli Lilly and in a report on Thursday, March 10th. They set an “outperform” rating and a $286.00 target price on the stock. Mizuho increased their price target on shares of Eli Lilly and from $315.00 to $356.00 in a research report on Monday, May 2nd. StockNews.com lowered shares of Eli Lilly and from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Finally, JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and from $340.00 to $355.00 in a research note on Wednesday, June 1st. Three research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and presently has an average rating of “Moderate Buy” and a consensus price target of $311.00.

About Eli Lilly and (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Stories

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.